Yapp–Schiff Disease (Hypophosphatasia Variant) – A Complete Medical Guide

Overview

Yapp–Schiff disease is a rare, inherited metabolic bone disorder that belongs to the spectrum of hypophosphatasia (HPP). It is named after the clinicians who first described the condition in the early 1970s. While classic hypophosphatasia can present at any age, the Yapp–Schiff variant typically manifests in childhood with a combination of skeletal, dental, and systemic abnormalities caused by low activity of the enzyme tissue‑non‑specific alkaline phosphatase (TNSALP).

• Who it affects: Both males and females inherit the disease in an autosomal‑recessive manner, although rare autosomal‑dominant forms have been reported. Families of European, Middle‑Eastern, and Asian descent have documented cases, but the condition is globally distributed.
• Prevalence: Hypophosphatasia overall has an estimated prevalence of 1 per 100,000–300,000 live births. The Yapp–Schiff variant accounts for roughly 10‑15 % of all reported HPP cases, translating to about 1‑3 per million individuals worldwide.^{[1] NIH Office of Rare Diseases}
• Prognosis: When diagnosed early and treated with enzyme replacement therapy (asfotase alfa) or supportive measures, most children achieve near‑normal growth and avoid severe complications. Untreated severe forms can lead to early mortality.

Symptoms

Symptoms vary widely depending on age of onset and severity, but the Yapp–Schiff variant characteristically presents in early childhood (typically 6 months‑5 years). The table below outlines the complete symptom profile.

Causes and Risk Factors

Genetic Basis

The disease is caused by pathogenic variants in the ALPL gene, which encodes TNSALP. Loss‑of‑function mutations reduce the enzyme’s ability to dephosphorylate inorganic pyrophosphate (PPi), a natural inhibitor of mineralization. Accumulation of PPi leads to defective bone and tooth mineralization.

Inheritance Pattern

• Autosomal‑recessive (AR): Two defective copies are required; carriers are asymptomatic.
• Autosomal‑dominant (AD) rare forms: A single severe mutation can cause a milder phenotype.

Risk Factors

• Consanguineous parents (higher chance of AR inheritance).
• Family history of hypophosphatasia or unexplained early tooth loss.
• Ethnic groups with known founder mutations (e.g., certain Middle‑Eastern, Mediterranean, or Asian populations).

Diagnosis

Diagnosing Yapp–Schiff disease involves a combination of clinical evaluation, laboratory testing, imaging, and genetic analysis.

Laboratory Tests

• Serum alkaline phosphatase (ALP): Markedly low for age (often < 30 U/L in children).
• Serum calcium and phosphate: May be elevated or normal; hypercalcemia is common in infants.
• Pyridoxal‑5‑phosphate (PLP): Elevated because TNSALP can’t convert PLP to pyridoxal.
• Urinary phosphoethanolamine (PEA): Increased excretion is a hallmark.

Imaging

• Radiographs: Show metaphyseal cupping, widening, and delayed epiphyseal ossification. “Rachitic” changes may be evident.
• Bone densitometry (DXA): Low bone mineral density (Z‑score ≤ ‑2.0).
• Dental X‑rays: Early loss of cementum and dentin.

Genetic Testing

Sequencing of the ALPL gene confirms the diagnosis and differentiates the Yapp–Schiff variant from other HPP forms. Testing is recommended for the patient and both parents to establish carrier status.

Diagnostic Criteria (adapted from the International HPP Consensus Group)

1. Clinical features consistent with HPP (bone pain, fractures, premature tooth loss, etc.).
2. Serum ALP below the age‑specific reference range.
3. Either a pathogenic ALPL variant or elevated PLP/PEA.

Treatment Options

Therapeutic goals are to restore bone mineralization, relieve pain, prevent fractures, and improve quality of life.

Enzyme Replacement Therapy (ERT)

Asfotase alfa (brand name Strensiq®) is a recombinant human TNSALP approved by the FDA (2015) and EMA (2015) for pediatric-onset HPP, including the Yapp–Schiff variant.

• Dosage: 2 mg/kg subcutaneously three times per week (or 1 mg/kg daily).
• Benefits: Increases ALP activity, reduces PLP levels, promotes skeletal mineralization, improves height velocity, and often restores normal dentition.
• Side effects: Injection‑site reactions, lipodystrophy, ectopic calcifications (rare).

Long‑term data (5‑year follow‑up) show sustained improvements in height and reduced fracture rates ^{[2] Clin. Ther. 2022}.

Supportive & Symptomatic Care

• Pain management: Acetaminophen or NSAIDs as needed; avoid high‑dose aspirin in children.
• Calcium & vitamin D supplementation: Only if labs show deficiency; excessive calcium can worsen hypercalcemia.
• Orthopedic interventions: Brace fitting for thoracic insufficiency, surgical correction of severe deformities, or fracture stabilization.
• Dental care: Early referral to a pediatric dentist; removable dentures or dental implants after bone healing.

Lifestyle & Rehabilitation

• Low‑impact physical therapy to maintain muscle strength and joint range of motion.
• Weight‑bearing activities (e.g., walking on soft surfaces) as tolerated to stimulate bone growth.
• Nutrition focused on adequate protein, calcium (if not hypercalcemic), and vitamin D.

Living with Yapp–Schiff Disease (Hypophosphatasia Variant)

While a diagnosis can be daunting, many families find that a multidisciplinary approach enables a near‑normal childhood.

Practical Daily Management Tips

• Medication schedule: Keep a log for asfotase alfa injections; set reminders on a phone app.
• Monitor calcium levels: Quarterly blood tests for the first two years, then semi‑annually.
• Dental hygiene: Brush twice daily with fluoride toothpaste; schedule dental visits every 6 months.
• Safe environment: Use protective padding on hard surfaces; avoid high‑impact sports until bone density improves.
• School accommodations: Provide a note for extra breaks, permission to carry a water bottle, and exemption from activities that risk fractures.
• Psychosocial support: Connect with rare‑disease patient groups (e.g., National Organization for Rare Disorders) for emotional support.

Follow‑up Schedule

Prevention

Because Yapp–Schiff disease is genetic, primary prevention is not possible. However, families can take steps to reduce the impact and identify the condition early.

• Genetic counseling: Recommended for couples with a known carrier or affected child. Carrier testing can inform reproductive choices (prenatal diagnosis, pre‑implantation genetic testing).
• Newborn screening: Some regions are adding ALP measurement to newborn panels; early detection enables prompt treatment.
• Avoidance of risk‑enhancing factors: Do not give excess vitamin D or calcium supplements without medical supervision, as they can precipitate hypercalcemia.

Complications

If left untreated or poorly managed, several serious complications may arise.

• Progressive skeletal deformities: Severe rickets, bowed limbs, and thoracic insufficiency syndrome.
• Recurrent fractures: Leading to chronic pain, limited mobility, and dependence on caregivers.
• Dental loss and malocclusion: May affect nutrition and speech.
• Hypercalcemia‑related kidney damage: Nephrocalcinosis and renal insufficiency.
• Respiratory failure: Due to chest wall rigidity; the leading cause of mortality in severe infantile forms.
• Neurological sequelae: Seizures from vitamin B6 toxicity if not recognized.